Nearly £300 million will be invested in trials for weight-loss jabs under a new partnership between the government and a US pharmaceutical company.
Eli Lilly, which is thought to be the world’s biggest pharmaceutical company, announced that it will provide £279 million to fund research into ways to tackle the UK’s obesity crisis.
It will involve a five-year trial in Manchester testing the effectiveness of the weight-loss jab Mounjaro, or tirzepatide, the main rival to Ozempic.
Nearly £300 million will be invested into weigh loss trials with Eli Lilly
DIMPLE BHATI/GETTY IMAGES
The drug will be delivered in community settings and the results of the trial will inform NHS plans for a large-scale roll out of weight-loss drugs. Researchers will also examine other ways to help people lose weight, including digital tools such as apps to encourage people to adopt a